OncoMatch/Clinical Trials/NCT03590171
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Is NCT03590171 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Bortezomib for acute lymphoblastic leukemia (all).
Treatment: Bortezomib — The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Excluded: BCR fusion with ABL1 (t(9;22))
Breakpoint cluster region-Abelson (BCR-ABL)/ t(9;22) positive ALL
Excluded: ABL1 fusion with BCR (t(9;22))
Breakpoint cluster region-Abelson (BCR-ABL)/ t(9;22) positive ALL
Disease stage
Required: Stage 1ST RELAPSE
Meeting HR criteria any BM relapse, early/very early isolated BM relapse, very early isolated/combined extramedullary relapse
Prior therapy
Cannot have received: allogeneic stem cell transplant
Relapse post allogeneic stem-cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify